Previous 10 | Next 10 |
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
-- Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients -- Enrollment in posoleucel pivotal Phase 3 multi-virus prevention, virus-assoc...
AlloVir Inc. (ALVR) is expected to report $-0.42 for Q3 2023
2023-09-21 14:44:37 ET Shares of AlloVir (NASDAQ: ALVR) fell as much as 7% early Thursday, then largely recovered to trade down around 0.7% as of 1:40 p.m. ET amid concerns over a lock-up agreement expiration for certain restricted stock units of the late clinical-stage cell therapy...
2023-09-18 13:13:33 ET For further details see: TTOO, ASTR and MBOT among mid-day movers
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference ...
2023-08-22 12:49:05 ET More on AlloVir AlloVir: 'Takes One To Know One' AlloVir: Several Late-Stage Programs Make This Worth A Look AlloVir spikes as Bank of America starts at Buy on lead asset AlloVir spikes as Gilead buys over $10M stock AlloVir gai...
2023-08-21 13:08:17 ET Gainers: Timber Pharmaceuticals ( TMBR ) +97% . China SXT Pharmaceuticals ( SXTC ) +92% . Novo Integrated Sciences ( NVOS ) +43% . Orchestra BioMed Holdings ( OBIO ) +27% . AlloVir ( ALVR ) +26% . The G...
AlloVir, Inc. (NASDAQ: ALVR) is one of today's top gainers. The company's shares are currently up 22.54% on the day to $3.48. Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies t...
2023-08-21 11:52:45 ET More on Health Care Select Sector SPDR XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air Goldman add...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. Company Name:
ALVR Stock Symbol:
NASDAQ Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...